Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047557 | 0.90 | KMO (0.52) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL3058830 | 0.84 | HSD17B1 (0.50) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL13139523 | 0.84 | MEN1 (0.46) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL3061861 | 0.82 | MEN1 (0.48) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL13139524 | 0.80 | HTR6 (0.46) | MEN1KMT2AHTR6LMNAMAPT | |
| SCHEMBL27422020 | 0.80 | MEN1 (0.57) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL13139531 | 0.80 | HSD17B1 (0.43) | MEN1KMT2AHSD17B1HSD17B2LMNA | |
| SCHEMBL3063588 | 0.78 | HTR6 (0.51) | HTR6 | |
| SCHEMBL27421833 | 0.76 | MEN1 (0.55) | MEN1KMT2AHSD17B1HSD17B2HTR6 | |
| SCHEMBL3055485 | 0.75 | BDKRB1 (0.38) | MEN1KMT2AHTR6LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492559-B2 | Substituted indole compounds | GRUENENTHAL GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222324-A1 | Substituted Indole Compounds | GRUENENTHAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222324-A1 | Substituted Indole Compounds | BDKRB1, BDKRB2, EDNRB | MEN1 1256/4885KMT2A 2512/4885HSD17B1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.